Reimbursement For Shockwave’s IVL Device May Pose Quandary For CMS

A temporary reimbursement boost for Shockwave’s C2 coronary intravascular lithotripsy (IVL) is coming to an end. John Leppard, Senior Healthcare Analyst & VP at Washington Analysis breaks down what that means for CMS.